Aldeyra CEO Showcases Reproxalap Ahead of March 16 FDA PDUFA Decision
Aldeyra Therapeutics CEO highlighted lead candidate reproxalap at the Oppenheimer Conference, emphasizing its novel inflammatory pathway targeting ahead of the FDA PDUFA date of March 16, 2026. He underscored positive safety and efficacy signals supporting reproxalap’s potential first approval in ocular inflammatory disorders.
1. CEO Presentation
At the Oppenheimer Healthcare conference, Aldeyra’s CEO detailed reproxalap’s mechanism of action as a covalent inhibitor of aldehyde-mediated inflammation, emphasizing topline safety and efficacy results from late-stage trials. He framed the drug as a potential first-in-class treatment for multiple ocular inflammatory conditions.
2. FDA Timeline
Reproxalap’s New Drug Application is under review with a set PDUFA action date on March 16, 2026. This milestone will determine whether reproxalap can advance to commercialization and generate initial revenue streams.
3. Market Implications
Approval could position Aldeyra as a pioneer in ocular inflammation, unlocking a new therapeutic category with limited competition. Investors are weighing projected peak sales potential against development risks ahead of the FDA decision.